Colombia acts to secure generic HIV drug amid rising infections

Colombia has taken significant steps to address the rising HIV infection rates in its population, which currently stands at approximately 230,000 cases, making it the third highest in Latin America. In April 2023, the Colombian government announced a compulsory licence for dolutegravir, a preferred first-line antiretroviral treatment recommended by the World Health Organization. This move allows the country to procure generic versions of the drug at a fraction of the cost, enabling treatment for nearly 26 individuals for the price of one branded medication. The decision to issue the licence was influenced by the need to support not only Colombian citizens but also the large number of Venezuelans living in the country, many of whom lack access to healthcare. Healthcare advocates have praised the government's action, emphasizing the importance of dolutegravir for individuals who may have inconsistent access to medication. However, there are concerns regarding the reliability of the supply chain, as some advocates express distrust in the government's ability to maintain a continuous supply of the drug. The Colombian Ministry of Health is currently negotiating with the Pan American Health Organization to secure a steady supply of dolutegravir. This initiative is seen as a crucial step in combating the HIV epidemic in Colombia, particularly in light of the challenges faced by marginalized communities, including the LGBTQ population and Venezuelan migrants. Overall, Colombia's proactive approach to securing access to essential HIV medication reflects a broader commitment to public health and the well-being of its citizens, while also addressing the needs of vulnerable populations within its borders.